The new force from ITRI joint the biomedical industry. The new breakthrough of “MegaPro Biomedical” drug benefits chronic kidney disease patients.

 Home News The new force from ITRI joint the biomedical industry. The new breakthrough of “MegaPro Biomedical” drug benefits chronic kidney disease patients.

The new force from ITRI joint the biomedical industry. The new breakthrough of “MegaPro Biomedical” drug benefits chronic kidney disease patient.

There is a new breakthrough in the development of iron supplement for the chronic kidney disease! “MegaPro Biomedical”, the new biotechnology company from ITRI was officially established on March 19th, benefiting chronic kidney disease patients with fast and effective iron supplement. MegaPro Biomedical focuses on the development of iTrast iron oxide nanoparticle, the iron supplement for chronic kidney disease, and joins the fight for market shares in the area of chronic kidney disease iron deficiency anemia therapy with a single injection and hypoallergenic property.

There is a new breakthrough in the development of iron supplement for the chronic kidney disease! “MegaPro Biomedical”, the new biotechnology company from ITRI was officially established on March 19th, benefiting chronic kidney disease patients with fast and effective iron supplement. MegaPro Biomedical focuses on the development of iTrast iron oxide nanoparticle, the iron supplement for chronic kidney disease, and joins the fight for market shares in the area of chronic kidney disease iron deficiency anemia therapy with a single injection and hypoallergenic property.

Jiang, Wei-Feng, the Chairman of MegaPro Biomedical, said that patients with chronic kidney disease usually have iron deficiency anemia. There are about 450 million people suffering from the third to fifth stages of chronic kidney disease worldwide and 40% of these people require iron supplement injection due to iron deficiency anemia. Hence, it is expected that the global market size for iron supplement injection will reach 1.6 billion in 2015. According to statistics from the National Health Insurance Administration, Taiwan has the highest dialysis population density in the world. Currently, there are about 70,000 dialysis patients in Taiwan and this number is growing rapidly at the rate of 3,000 people per year. The iTrast that MegaPro Biomedical is developing can provide sufficient iron supplement through a single injection, satisfying the fast-growing demand for iron supplements while providing a simpler solution for these patients with chronic kidney disease. In the future, MegaPro Biomedical will focus on the development of niche drugs with an emphasis on added value for human clinical trial and preclinical testing stage. The company also aims to provide top-notch biomedical technology for nanoparticles and nano-micelle and license the products to pharmaceutical companies. It will develop more preclinical drugs and contribute to medical treatment in the future.

Jassy Wang, CEO of MegaPro Biomedical, said that the chronic kidney disease patients in the past need to go to the hospital weekly or fortnightly for iron ion inject due the iron deficiency. Each treatment requires 5-10 injections in the hospital and takes up to 2-3 months to complete. There can also be allergic reaction to high ion dosage and is hence inconvenient for patients with chronic kidney disease. The iTrast from MegaPro Biomedical consists of iron oxide nanoparticle which can be injected in one shot. This eliminates the need for multiple treatments and the product has high biocompatibility and low toxicity. It can be easily converted and stored as ferritin in the liver and release into the bloodstream when needed, treating anemia. It is expected that animal testing would be completed in the latter half of the year. This would be followed by clinical trials before joining the fight for the market share in the global intravenous iron supplement injection market worth more than 1.6 billion USD annually.

source: https://www.itri.org.tw/chi/Content/NewsLetter/Contents.aspx?SiteID=1&MmmID=620605426331276153&MSid=653412113532735761